{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:10:13Z","timestamp":1791897013720,"version":"4.3.4"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi & Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cefiderocol is a novel siderophore cephalosporin with promising activity against most carbapenem-resistant Gram-negative bacteria (CRGNB). However, extensive postmarketing experiences are lacking. This study aimed to analyse the early experience on cefiderocol postmarketing use at three tertiary care hospitals in Italy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively included patients with infections caused by CRGNB treated with cefiderocol at three Italian tertiary care hospitals from 1 March 2021 to 30 June 2022. A multivariate Cox model was used to identify predictors of 30\u2005day mortality. A propensity score (PS) analysis with inverse probability weighting (IPW) was also performed to compare the treatment effect of cefiderocol monotherapy (CM) versus combination regimens (CCRs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The cohort included 142 patients (72% male, median age 67\u2005years, with 89 cases of Acinetobacter baumannii infection, 22 cases of Klebsiella pneumoniae, 27 cases of Pseudomonas aeruginosa and 4 of other pathogens). The 30\u2005day all-cause mortality was 37% (52\/142). We found no association between bacterial species and mortality. In multivariate analysis, a Charlson Comorbidity Index &amp;gt;3 was an independent predictor of mortality (HR 5.02, 95% CI 2.37\u201310.66, P\u200a&amp;lt;\u200a0.001). In contrast, polymicrobial infection (HR 0.41, 95% CI 0.21\u20130.82, P\u200a&amp;lt;\u200a0.05) was associated with lower mortality. There was no significant difference in mortality between patients receiving CM (n\u200a=\u200a70) and those receiving a CCR (n\u200a=\u200a72) (33% versus 40%, respectively), even when adjusted for IPW-PS (HR 1.11, 95% CI 0.63\u20131.96, P\u200a=\u200a0.71).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Real-life data confirm that cefiderocol is a promising option against carbapenem-resistant Gram-negative infections, even as monotherapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkad298","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T13:03:18Z","timestamp":1696856598000},"page":"2752-2761","source":"Crossref","is-referenced-by-count":36,"title":["Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience"],"prefix":"10.1093","volume":"78","author":[{"given":"Matteo","family":"Piccica","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Spinicci","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence , Italy"},{"name":"Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Careggi , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Botta","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and Infectious Emergencies, AORN dei Colli, Cotugno Hospital , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bianco","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and Infectious Emergencies, AORN dei Colli, Cotugno Hospital , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Lagi","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Careggi , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Graziani","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Faragona","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Public Health, Universit\u00e0 Politecnica delle Marche , Ancona , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Parrella","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease and Infectious Emergencies, AORN dei Colli, Cotugno Hospital , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Giani","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence , Italy"},{"name":"Clinical Microbiology and Virology Unit, Florence Careggi University Hospital , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bartolini","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0772-0214","authenticated-orcid":false,"given":"Gianluca","family":"Morroni","sequence":"additional","affiliation":[{"name":"Clinic of Infectious Diseases, Azienda Ospedaliero-Universitaria delle Marche , Ancona , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Bernardo","sequence":"additional","affiliation":[{"name":"Microbiology Unit, AORN Ospedali dei Colli-Monaldi Hospital , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9386-0434","authenticated-orcid":false,"given":"Gian Maria","family":"Rossolini","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence , Italy"},{"name":"Clinical Microbiology and Virology Unit, Florence Careggi University Hospital , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tavio","sequence":"additional","affiliation":[{"name":"Unit of Emerging and Immunosuppressed Infectious Diseases, Department of Gastroenterology and Transplantation, Azienda Ospedaliero-Universitaria \u2018Ospedali Riuniti\u2019 , Ancona , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giacometti","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Public Health, Universit\u00e0 Politecnica delle Marche , Ancona , Italy"},{"name":"Clinic of Infectious Diseases, Azienda Ospedaliero-Universitaria delle Marche , Ancona , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bartoloni","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence , Florence , Italy"},{"name":"Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Careggi , Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"2023110823043728600_dkad298-B1","volume-title":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","author":"WHO","year":"2017"},{"key":"2023110823043728600_dkad298-B2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/jpids\/piz002","article-title":"Defining the role of novel \u03b2-lactam agents that target carbapenem-resistant Gram-negative organisms","volume":"8","author":"Tamma","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2023110823043728600_dkad298-B3","doi-asserted-by":"crossref","first-page":"e01454-17","DOI":"10.1128\/AAC.01454-17","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria","volume":"62","author":"Ito","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023110823043728600_dkad298-B4","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2023110823043728600_dkad298-B5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023110823043728600_dkad298-B6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023110823043728600_dkad298-B7","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/antibiotics12040746","article-title":"Cefiderocol efficacy in a real-life setting: single-centre retrospective study","volume":"12","author":"Palermo","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2023110823043728600_dkad298-B8","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3390\/antibiotics12050936","article-title":"Clinical outcome of cefiderocol for infections with carbapenem-resistant organisms","volume":"12","author":"Sajib","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2023110823043728600_dkad298-B9","doi-asserted-by":"crossref","first-page":"e0019423","DOI":"10.1128\/aac.00194-23","article-title":"Cefiderocol treatment for patients with multidrug- and carbapenem-resistant Pseudomonas aeruginosa infections in the compassionate use program","volume":"67","author":"Satlin","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2023110823043728600_dkad298-B10","doi-asserted-by":"crossref","first-page":"dlad085","DOI":"10.1093\/jacamr\/dlad085","article-title":"Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. baumannii ventilator-associated pneumonia: a propensity-weighted cohort study","volume":"5","author":"Rando","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"2023110823043728600_dkad298-B11","author":"Shionogi Inc.","year":"2020"},{"key":"2023110823043728600_dkad298-B12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2023110823043728600_dkad298-B13","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"2023110823043728600_dkad298-B14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/qjmed\/94.10.521","article-title":"Validation of a modified Early Warning Score in medical admissions","volume":"94","author":"Subbe","year":"2001","journal-title":"QJM"},{"key":"2023110823043728600_dkad298-B15","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)"},{"key":"2023110823043728600_dkad298-B16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"2023110823043728600_dkad298-B17","first-page":"2526","article-title":"Acute respiratory distress syndrome: the Berlin definition","volume":"307","author":"ARDS Definition Task Force","year":"2012","journal-title":"JAMA"},{"key":"2023110823043728600_dkad298-B18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"2023110823043728600_dkad298-B19","doi-asserted-by":"crossref","first-page":"2200795","DOI":"10.2807\/1560-7917.ES.2022.27.43.2200795","article-title":"Nosocomial outbreak by NDM-1-producing Klebsiella pneumoniae highly resistant to cefiderocol, Florence, Italy, August 2021 to June 2022","volume":"27","author":"Coppi","year":"2022","journal-title":"Euro Surveill"},{"key":"2023110823043728600_dkad298-B20","doi-asserted-by":"crossref","first-page":"e0201121","DOI":"10.1128\/aac.02011-21","article-title":"New Delhi metallo-beta-lactamase facilitates the emergence of cefiderocol resistance in Enterobacter cloacae","volume":"66","author":"Nurjadi","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023110823043728600_dkad298-B21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2023110823043728600_dkad298-B22","doi-asserted-by":"crossref","first-page":"e00951-20","DOI":"10.1128\/JCM.00951-20","article-title":"Cefiderocol antimicrobial susceptibility testing considerations: the Achilles\u2019 heel of the Trojan horse?","volume":"59","author":"Simner","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2023110823043728600_dkad298-B23","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(21)00194-8","article-title":"Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens","volume":"21","author":"Choby","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2023110823043728600_dkad298-B24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-021-01061-7","article-title":"Penetration of antibacterial agents into pulmonary epithelial lining fluid: an update","volume":"61","author":"Drwiega","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2023110823043728600_dkad298-B25","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/jac\/dkz123","article-title":"Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects","volume":"74","author":"Katsube","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023110823043728600_dkad298-B26","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jcph.1986","article-title":"Intrapulmonary pharmacokinetic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia and healthy subjects","volume":"62","author":"Kawaguchi","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"2023110823043728600_dkad298-B27","doi-asserted-by":"crossref","first-page":"evidoa2200131","DOI":"10.1056\/EVIDoa2200131","article-title":"Colistin monotherapy versus combination therapy for carbapenem-resistant organisms","volume":"2","author":"Kaye","year":"2023","journal-title":"NEJM Evid"},{"key":"2023110823043728600_dkad298-B28","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1093\/cid\/ciad097","article-title":"Pathogen-targeted clinical development to address unmet medical need: design, safety, and efficacy of the ATTACK trial","volume":"76","author":"Watkins","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023110823043728600_dkad298-B29","doi-asserted-by":"crossref","first-page":"e0214221","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023110823043728600_dkad298-B30","doi-asserted-by":"crossref","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","article-title":"Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2023110823043728600_dkad298-B31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2023110823043728600_dkad298-B32","doi-asserted-by":"crossref","first-page":"dlab188","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2023110823043728600_dkad298-B33","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/microorganisms9020282","article-title":"Susceptibility testing is key for the success of cefiderocol treatment: a retrospective cohort study","volume":"9","author":"Bleibtreu","year":"2021","journal-title":"Microorganisms"},{"key":"2023110823043728600_dkad298-B34"},{"key":"2023110823043728600_dkad298-B35","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2023110823043728600_dkad298-B36","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","article-title":"Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023110823043728600_dkad298-B37","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jiph.2022.07.006","article-title":"Cefiderocol use in Gram negative infections with limited therapeutic options: is combination therapy the key?","volume":"15","author":"Corcione","year":"2022","journal-title":"J Infect Public Health"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/11\/2752\/52814503\/dkad298.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/11\/2752\/52814503\/dkad298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T23:05:18Z","timestamp":1699484718000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/11\/2752\/7300972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,10,9]]},"published-print":{"date-parts":[[2023,11,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad298","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,10,9]]}}}